An early stage clinical study shows removing a protein known as soluble Fms-like tyrosine kinase 1 (sFlt-1) from the blood of pregnant women with early stage, severe preeclampsia seems to help both mothers and babies with no significant side effects.
The treatment, which involved filtering the patient’s blood through a machine to remove the harmful protein, reduced blood pressure and allowing pregnancies to continue for around 10 extra days.
Up to 5% of pregnancies in the U.S. are affected by preeclampsia, a condition where a woman develops high blood pressure during pregnancy, and organs like the kidneys, liver, or brain can also be affected. It can be life threatening in some cases and there are currently no available treatments, so the only real option is to deliver the baby, which can cause problems for the baby if delivered preterm.
The single exact cause of preeclampsia is unknown, but most evidence points to problems with how the placenta and its blood vessels develop early in pregnancy, which then triggers widespread damage in the mother’s blood vessels. Women with preeclampsia seem to have high levels of sFlt-1 in their blood and research suggests it binds and neutralizes VEGF and PlGF, key proteins that normally help keep blood vessels healthy and relaxed.
In this study, published in Nature Medicine, the researchers tested whether filtering the blood of women with early onset preeclampsia (at 24-32 weeks gestation) to remove the excess sFlt-1 protein could help improve their symptoms and prolong pregnancy.
This was an early stage study to check safety and tolerability and included 16 women in total. Seven women were in an initial group to test the safety of the filtering process and to assess how much protein could be removed. This showed the treatment was safe and well tolerated with no major side effects observed.
The second group of nine women had several treatments and the researchers looked at how effective the treatment was in this group. In the second group, the women’s symptoms improved; blood pressure went down by 4.1 mmHg on average and pregnancy was extended by 3-19 days (median 10 days).
“Even a few extra days in the womb can make a meaningful difference in outcomes for premature infants,” said co-lead study author Ananth Karumanchi, MD, professor of medicine and director of the Renovascular Research Center at Cedars-Sinai, in a press statement. “We found a way to potentially buy that time safely. Our approach could shift how we manage very early preeclampsia.”
The researchers acknowledge the treatment needs to be tested further but are hopeful it could be a good treatment option for women with this condition in the future, particularly as it does not involve introducing a drug or therapy into the body and therefore reduces the risk of side effects for both mother and baby.
The post Removing Harmful Protein from Blood Helps Women with Preeclampsia appeared first on Inside Precision Medicine.